Judge Rules in Favor of FDA in Ranbaxy Drug Approval Suit

Mar 17, 2015

U.S. District Judge Beryl Howell ruled that the FDA is within its right to revoke approval of Ranbaxy's generic Nexium (esomeprazole) and Valcyte (valganciclovir).

As reported by BioPharmaDive, after the FDA revoked the two ANDAs from Ranbaxy, six years after granting them, it subsequently granted approvals for the same two drugs to three other companies, including Endo, Dr. Reddy's and Teva. Ranbaxy responded last November by suing FDA for revoking the tentative approvals.

Although Judge Howell chastised the FDA for taking so long to revoke the approvals, the FDA claimed Ranbaxy was unresponsive to all attempts to further the investigation of cGMP vioations at manufacturing facilities, thus delaying the eventual ANDA revocation.


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments